Opinion|Videos|October 8, 2024
Unmet Needs in the HFmrEF and HFpEF Landscape
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations.
- Emerging treatments could reduce hospitalization rates and enhance quality of life for patients with HFmrEF and HFpEF.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Based on the new data from the 3 abstracts, what unmet needs could the therapies address within the heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF landscape?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Bringing CAR T-Cell Therapy Into Community Cancer Centers
2
The True Cost of Running a Community CAR T-Cell Program
3
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
4
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
5